Table of Contents
ISRN Obstetrics and Gynecology
Volume 2011, Article ID 292951, 9 pages
http://dx.doi.org/10.5402/2011/292951
Clinical Study

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial

1Gyneco-obstetric Hospital Ramon Gonzalez Coro, Havana 10400, Cuba
2Clinical Trials Division, Center for Biological Research, Havana 6996, Cuba
3Gyneco-obstetric Hospital Mariana Grajales, Santa Clara 50100, Cuba
4General Hospital Carlos Manuel de Céspedes, Bayamo 85100, Cuba
5Department of Cancer, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Havana 10600, Cuba
6Department of Genomics, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba

Received 5 January 2011; Accepted 26 January 2011

Academic Editors: R. M. Austin and K. Chan

Copyright © 2011 Ana M. Solares et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Koutsky, K. K. Holmes, C. W. Critchlow et al., “A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection,” The New England Journal of Medicine, vol. 327, no. 18, pp. 1272–1278, 1992. View at Google Scholar
  2. N. Muñoz, F. X. Bosch, S. de Sanjosé et al., “Epidemiologic classification of human papillomavirus types associated with cervical cancer,” The New England Journal of Medicine, vol. 348, no. 6, pp. 518–527, 2003. View at Publisher · View at Google Scholar · View at PubMed
  3. M. Schiffman and S. K. Kjaer, “Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia,” Journal of the National Cancer Institute. Monographs, no. 31, pp. 14–19, 2003. View at Google Scholar
  4. A. Ferenczy and E. Franco, “Persistent human papillomavirus infection and cervical neoplasia,” The Lancet Oncology, vol. 3, no. 1, pp. 11–16, 2002. View at Publisher · View at Google Scholar
  5. P. E. Castle, M. Schiffman, M. C. Bratti et al., “A population-based study of vaginal human papillomavirus infection in hysterectomized women,” Journal of Infectious Diseases, vol. 190, no. 3, pp. 458–467, 2004. View at Publisher · View at Google Scholar · View at PubMed
  6. M. Kyrgiou, G. Koliopoulos, P. Martin-Hirsch, M. Arbyn, W. Prendiville, and E. Paraskevaidis, “Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions:systematic review and meta-analysis,” The Lancet, vol. 367, no. 9509, pp. 489–498, 2006. View at Publisher · View at Google Scholar · View at PubMed
  7. J. A. Brinkman, S. H. Hughes, P. Stone et al., “Therapeutic vaccination for HPV induced cervical cancers,” Disease Markers, vol. 23, no. 4, pp. 337–352, 2007. View at Google Scholar
  8. S. Kanodia, D. M. Da Silva, and W. M. Kast, “Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions,” International Journal of Cancer, vol. 122, no. 2, pp. 247–259, 2008. View at Publisher · View at Google Scholar · View at PubMed
  9. C. Mesa and L. E. Fernández, “Challenges facing adjuvants for cancer immunotherapy,” Immunology and Cell Biology, vol. 82, no. 6, pp. 644–650, 2004. View at Publisher · View at Google Scholar · View at PubMed
  10. C. Mesa, J. de León, K. Rigley, and L. E. Fernández, “Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation,” Vaccine, vol. 22, no. 23-24, pp. 3045–3052, 2004. View at Publisher · View at Google Scholar · View at PubMed
  11. I. Torréns, O. Mendoza, A. Batte et al., “Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors,” Vaccine, vol. 23, no. 50, pp. 5768–5774, 2005. View at Publisher · View at Google Scholar · View at PubMed
  12. M. E. Ressing, A. Sette, R. M. P. Brandt et al., “Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A0201-binding peptides,” Journal of Immunology, vol. 154, no. 11, pp. 5934–5943, 1995. View at Google Scholar
  13. Cancer Therapy Evaluation Program, common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS 2003, http://ctep.cancer.gov/.
  14. A. Stafl and G. D. Wilbanks, “An international terminology of colposcopy: report of the nomenclature committee of the International Federation of Cervical Pathology and Colposcopy,” Obstetrics and Gynecology, vol. 77, no. 2, pp. 313–314, 1991. View at Google Scholar
  15. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Google Scholar
  16. M. Bunce and K. Welsh, “PCR-SSP typing of HLA class I and class II alleles,” in ASHI Laboratory Manual, A. B. Hahn, G. A. Land, and R. M. Strothman, Eds., pp. 1–19, ASHI Publications, 4th edition, 2000. View at Google Scholar
  17. M. V. Jacobs, P. J. F. Snijders, A. J. C. van den Brule, T. J. M. Helmerhorst, C. J. L. M. Meijer, and J. M. M. Walboomers, “A general primer GP5+/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings,” Journal of Clinical Microbiology, vol. 35, no. 3, pp. 791–795, 1997. View at Google Scholar
  18. L. W. Huang, S. L. Chao, P. H. Chen, and H. P. Chou, “Multiple HPV genotypes in cervical carcinomas: improved DNA detection and typing in archival tissues,” Journal of Clinical Virology, vol. 29, no. 4, pp. 271–276, 2004. View at Publisher · View at Google Scholar · View at PubMed
  19. M. Nakagawa, D. P. Stites, S. Farhat et al., “T-Cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia,” Clinical and Diagnostic Laboratory Immunology, vol. 3, no. 2, pp. 205–210, 1996. View at Google Scholar
  20. M. E. Ressing, W. J. van Driel, E. Celis et al., “Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A0201-restricted E7-encoded epitope,” Cancer Research, vol. 56, no. 3, pp. 582–588, 1996. View at Google Scholar
  21. M. Nimako, A. N. Fiander, G. W. G. Wilkinson, L. K. Borysiewicz, and S. Man, “Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III,” Cancer Research, vol. 57, no. 21, pp. 4855–4861, 1997. View at Google Scholar
  22. M. A. Steller, K. J. Gurski, M. Murakami et al., “Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7,” Clinical Cancer Research, vol. 4, no. 9, pp. 2103–2109, 1998. View at Google Scholar
  23. W. van Driel, M. E. Ressing, G. G. Renter et al., “Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial,” European Journal of Cancer, vol. 35, no. 6, pp. 946–952, 1999. View at Publisher · View at Google Scholar
  24. M. E. Ressing, W. J. van Driel, R. M.P. Brandt et al., “Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma,” Journal of Immunotherapy, vol. 23, no. 2, pp. 255–266, 2000. View at Publisher · View at Google Scholar
  25. L. Muderspach, S. Wilczynski, L. Roman et al., “A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive,” Clinical Cancer Research, vol. 6, no. 9, pp. 3406–3416, 2000. View at Google Scholar
  26. A. M. Kaufmann, P. L. Stern, E. M. Rankin et al., “Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer,” Clinical Cancer Research, vol. 8, no. 12, pp. 3676–3685, 2002. View at Google Scholar
  27. P. J. Baldwin, S. H. van der Burg, C. M. Boswell et al., “Vaccinia-expressed human papillomavirus 16 and 18 E6 and E7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia,” Clinical Cancer Research, vol. 9, no. 14, pp. 5205–5213, 2003. View at Google Scholar
  28. E. J. Davidson, R. L. Faulkner, P. Sehr et al., “Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7),” Vaccine, vol. 22, no. 21-22, pp. 2722–2729, 2004. View at Publisher · View at Google Scholar · View at PubMed
  29. L. J. C. Smyth, M. I. E. van Poelgeest, E. J. Davidson et al., “Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination,” Clinical Cancer Research, vol. 10, no. 9, pp. 2954–2961, 2004. View at Publisher · View at Google Scholar
  30. C. M. Corona Gutierrez, A. Tinoco, T. Navarro et al., “Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus,” Human Gene Therapy, vol. 15, no. 5, pp. 421–431, 2004. View at Publisher · View at Google Scholar · View at PubMed
  31. B. Klencke, M. Matijevic, R. G. Urban et al., “Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101,” Clinical Cancer Research, vol. 8, no. 5, pp. 1028–1037, 2002. View at Google Scholar
  32. E. E. Sheets, R. G. Urban, C. P. Crum et al., “Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA,” American Journal of Obstetrics and Gynecology, vol. 188, no. 4, pp. 916–926, 2003. View at Publisher · View at Google Scholar
  33. I. H. Frazer, M. Quinn, J. L. Nicklin et al., “Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia,” Vaccine, vol. 23, no. 2, pp. 172–181, 2004. View at Publisher · View at Google Scholar · View at PubMed
  34. S. Hallez, P. Simon, F. Maudoux et al., “Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia,” Cancer Immunology, Immunotherapy, vol. 53, no. 7, pp. 642–650, 2004. View at Publisher · View at Google Scholar · View at PubMed
  35. N. R. Chu, H. B. Wu, T. C. Wu, L. J. Boux, M. I. Siegel, and L. A. Mizzen, “Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7,” Clinical and Experimental Immunology, vol. 121, no. 2, pp. 216–225, 2000. View at Publisher · View at Google Scholar
  36. L. D. Roman, S. Wilczynski, L. I. Muderspach et al., “A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia,” Gynecologic Oncology, vol. 106, no. 3, pp. 558–566, 2007. View at Publisher · View at Google Scholar · View at PubMed
  37. S. A. Rosenberg, J. C. Yang, and N. P. Restifo, “Cancer immunotherapy: moving beyond current vaccines,” Nature Medicine, vol. 10, no. 9, pp. 909–915, 2004. View at Publisher · View at Google Scholar · View at PubMed
  38. P. Matzinger, “Tolerance, danger, and the extended family,” Annual Review of Immunology, vol. 12, pp. 991–1045, 1994. View at Google Scholar
  39. J. Melnikow, J. Nuovo, A. R. Willan, B. K. S. Chan, and L. P. Howell, “Natural history of cervical squamous intraepithelial lesions: a meta-analysis,” Obstetrics and Gynecology, vol. 92, no. 4, pp. 727–735, 1998. View at Publisher · View at Google Scholar
  40. S. H. van der Burg, K. M. C. Kwappenberg, T. O'Neill et al., “Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens,” Vaccine, vol. 19, no. 27, pp. 3652–3660, 2001. View at Publisher · View at Google Scholar
  41. V. Pasquetto, H. H. Bui, R. Giannino et al., “HLA-A0201, HLA-A1101, and HLA-B0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products,” Journal of Immunology, vol. 175, no. 8, pp. 5504–5515, 2005. View at Google Scholar
  42. J. Lichen, T. M. Chong, C. L. McClurkan, J. Huang, B. T. Story, and D. M. Koelle, “Diversity in the acute CD8 T cell response to vaccinia virus in humans,” Journal of Immunology, vol. 175, no. 11, pp. 7550–7559, 2005. View at Google Scholar
  43. H. McShane and A. Hill, “Prime-boost immunisation strategies for tuberculosis,” Microbes and Infection, vol. 7, no. 5-6, pp. 962–967, 2005. View at Publisher · View at Google Scholar · View at PubMed
  44. A. de Jong, T. O'Neill, A. Y. Khan et al., “Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine,” Vaccine, vol. 20, no. 29-30, pp. 3456–3464, 2002. View at Publisher · View at Google Scholar
  45. L. J. C. Smyth, M. I. E. van Poelgeest, E. J. Davidson et al., “Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination,” Clinical Cancer Research, vol. 10, no. 9, pp. 2954–2961, 2004. View at Publisher · View at Google Scholar